What is the official website of AbbVie | Neuroscience ?

The official website of AbbVie | Neuroscience is https://www.abbvie.com/our-science/therapeutic-focus-areas/neuroscience.html.

What is AbbVie | Neuroscience's cybersecurity risk score?

AbbVie | Neuroscience has an AI-generated cybersecurity risk score of 757 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has AbbVie | Neuroscience experienced?

According to Rankiteo, AbbVie | Neuroscience currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has AbbVie | Neuroscience been affected by any supply chain cyber incidents ?

According to Rankiteo, AbbVie | Neuroscience has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does AbbVie | Neuroscience have SOC 2 Type 1 certification ?

According to Rankiteo, AbbVie | Neuroscience is not certified under SOC 2 Type 1.

Does AbbVie | Neuroscience have SOC 2 Type 2 certification ?

According to Rankiteo, AbbVie | Neuroscience does not hold a SOC 2 Type 2 certification.

Does AbbVie | Neuroscience comply with GDPR ?

According to Rankiteo, AbbVie | Neuroscience is not listed as GDPR compliant.

Does AbbVie | Neuroscience have PCI DSS certification ?

According to Rankiteo, AbbVie | Neuroscience does not currently maintain PCI DSS compliance.

Does AbbVie | Neuroscience comply with HIPAA ?

According to Rankiteo, AbbVie | Neuroscience is not compliant with HIPAA regulations.

Does AbbVie | Neuroscience have ISO 27001 certification ?

According to Rankiteo,AbbVie | Neuroscience is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does AbbVie | Neuroscience operate in ?

AbbVie | Neuroscience operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does AbbVie | Neuroscience have ?

AbbVie | Neuroscience employs approximately None employees people worldwide.

Does AbbVie | Neuroscience own any subsidiaries ?

AbbVie | Neuroscience presently has no subsidiaries across any sectors.

How many LinkedIn followers does AbbVie | Neuroscience have ?

AbbVie | Neuroscience's official LinkedIn profile has approximately 14,648 followers.

What is the NAICS classification code for AbbVie | Neuroscience ?

AbbVie | Neuroscience is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does AbbVie | Neuroscience have a Crunchbase profile ?

No, AbbVie | Neuroscience does not have a profile on Crunchbase.

Does AbbVie | Neuroscience have a LinkedIn profile ?

Yes, AbbVie | Neuroscience maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/abbvie-neuroscience.

How many cybersecurity incidents has AbbVie | Neuroscience experienced ?

As of June 15, 2026, Rankiteo reports that AbbVie | Neuroscience has experienced 2 cybersecurity incidents.

How many peer or competitor companies does AbbVie | Neuroscience have ?

AbbVie | Neuroscience has an estimated 5,686 peer or competitor companies worldwide.

What types of cybersecurity incidents has AbbVie | Neuroscience faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Vulnerability.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Boost Score +25 with badge (5 left)

757

/1000

Fair

782

/1000

Fair

AbbVie | Neuroscience Vendor Cyber Rating & Cyber Score

abbvie.com

Add Your Compliance Badge

Follow AbbVie’s Neuroscience page for news and updates about our commitment to help those living with and affected by the realities of neurological and psychiatric disorders such as Alzheimer’s disease, bipolar disorder and depression, major depressive disorder, migraine, Parkinson’s disease, spinal cord injuries, post-stroke spasticity, schizophrenia, and stroke. Review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html

AN A.I CyberSecurity Scoring

Scoring History

AbbVie | Neuroscience CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

AbbVie | Neuroscien...

Breach

100

6/2023

ABB0473723

Loading…

A.I.

AN Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AN

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AbbVie | Neuroscience in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for AbbVie | Neuroscience in 2026.

Incident Types AN vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AbbVie | Neuroscience in 2026.

Incident History - AN (X = Date, Y = Severity)

Loading…

SUBSIDIARY

AbbVie | Neuroscience Subsidiaries

AN

Pharmaceutical Manufacturing

Website: https://www.abbvie.com/our-science/therapeutic-focus-areas/neuroscience.html

Company Size: 10,001+ employees

AbbViePharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

Allergan AestheticsPharmaceutical Manufacturing

CoolSculptingMedical Equipment Manufacturing

BOTOX® Cosmetic (onabotulinumtoxinA)Pharmaceutical Manufacturing

Allergan Medical InstitutePharmaceutical Manufacturing

JUVÉDERM® Collection of FillersPharmaceutical Manufacturing

Allergan Aesthetics Plastic and Regenerative Medicine PortfolioMedical Equipment Manufacturing

Natrelle Breast ImplantsPharmaceutical Manufacturing

Pharmacyclics, an AbbVie CompanyPharmaceutical Manufacturing

OncologyPharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

ImmunologyPharmaceutical Manufacturing

Loading…

AbbVie | Neuroscience Similar Companies

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Loading…

NEWS

AbbVie | Neuroscience CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 12, 2026 01:00 PM

Centre for Neuro Skills Appoints Curtis Shipman as Chief Information Officer

Centre for Neuro Skills (CNS) announces the appointment of enterprise technology and cybersecurity leader, Curtis Shipman, as chief...

Read Article

March 06, 2026 05:48 AM

LeadHER in Security: Julia O’Toole, Co-Founder & Co-CEO, MyCena

Exploring how mathematics and neuroscience intersect with cybersecurity, MyCena Co-Founder and Co-CEO Julia O'Toole discusses reducing...

Read Article

January 06, 2026 08:00 AM

Cybersecurity still fails at the click

While cybersecurity is all about rational behaviour, neuroscience says vulnerabilities can arise due to specific situations,...

Read Article

December 29, 2025 08:00 AM

8 Hot College Majors to Pursue Around Delaware

Looking for a college major that will help you stand out from the crowd and succeed in your career? Here's where to start.

Read Article

November 28, 2025 08:00 AM

Designing a neuro-symbolic dual-model architecture for explainable and resilient intrusion detection in IoT networks

The Internet of Things (IoT) is rapidly evolving into a vast ecosystem of interconnected devices that serve diverse domains, including smart...

Read Article

November 03, 2025 08:00 AM

Towards the neuromorphic Cyber-Twin: an architecture for cognitive defense in digital twin ecosystems

IntroductionAs cyber-physical systems become increasingly virtualized, digital twins have emerged as essential components for real-time...

Read Article

October 07, 2025 07:00 AM

The neurosecurity stack: How we balance neurotechnology’s opportunity with security

Neurotechnology is no longer confined to research labs or science fiction. From brain-computer interfaces restoring movement in people with...

Read Article

September 16, 2025 07:00 AM

Turning Ideas into Algorithms

USF's new Master of Science in AI program welcomes students without deep computing backgrounds. As one of USF's first master's students...

Read Article

August 22, 2025 07:00 AM

Rachel James, AbbVie: Harnessing AI for corporate cybersecurity

Cybersecurity is in the midst of a fresh arms race, and the powerful weapon of choice in this new era is AI.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12175

SUMMARY

A vulnerability was detected in CodeAstro Student Attendance Management System 1.0. Impacted is an unknown function of the file /attendance-php/Admin/createStudents.php. Performing a manipulation of the argument admissionNumber results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 4.7)

cvss2

Base Score: 5.8

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:P/A:P

cvss3

Base Score: 4.7

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.2

REFERENCES

CVE-2026-12174

SUMMARY

A security vulnerability has been detected in D-Link DCS-935L 1.10.01. This issue affects the function snprintf of the file /web/cgi-bin/greece/rhea of the component HTTP Handler. Such manipulation of the argument data leads to format string. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-12183

SUMMARY

Nefteprodukttekhnika BUK TS-G Gas Station Automation System 2.9.1 through 2.10.2 on Linux contains an Improper Authentication vulnerability (CWE-287) in the system configuration module. The /php/ajax-login.php endpoint returns userid=1 (administrator) in response to any HTTP POST request that supplies arbitrary credentials (e.g., action=dologin&login=<any_value>&pwd=<any_value>), and subsequent privileged endpoints under /php/ajax-main.php and /modules/* do not validate a server-side session. A remote unauthenticated attacker can invoke any administrative action exposed by the configuration module, including reading and modifying user rules, fuel tank gauges, fuel dispensers, relays, cash registers, bank terminals, fuel cards, price and customer displays, cash collection, and pricing rules.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:L/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-6428

SUMMARY

SQL Injection in reports/catalogue_out.pl in Koha Community Koha through 22.11.37, 23.x, 24.x before 24.11.16, 25.05.x before 25.05.11, 25.11.x before 25.11.05, 26.05.x before 26.05.01, and 26.11.x before 26.11.00 allows an authenticated staff user with the Reports module flag to read arbitrary data from the Koha application database via the Filter URL parameter when the Criteria parameter matches /branchcode/. The vulnerable sink in sub calculate concatenates the unmodified Filter request parameter directly into a LIKE clause of the auxiliary $strsth2 statement and executes it via DBI without bound parameters: my $f = @$filters[0]; $f =~ s/\*/%/g; $strsth2 .= " AND $column LIKE '$f' "; This enables error-based SQL injection (e.g., via EXTRACTVALUE) and full read access to sensitive tables including borrowers (password hashes, 2FA secrets, PII), borrower_password_recovery, api_keys, and sessions. Proof of concept (error-based, single request): GET /cgi-bin/koha/reports/catalogue_out.pl?do_it=1&output=screen&Limit=10&Criteria=branchcode&Filter=x'+AND+EXTRACTVALUE(1,CONCAT(0x7e,VERSION(),0x7c,USER(),0x7c,DATABASE(),0x7e))--+- Cookie: CGISESSID=<LIBRARIAN_SESSION> The response body contains the DBI exception leaking the MariaDB version, database user, client IP, and database name, after which arbitrary data can be paged out using LIMIT n,1 / SUBSTRING(...). The vulnerable sink was introduced in commit 6bb77ae3e4 (2008-07-09); CVE-2015-4633 patched the same class in sibling files but did not generalise the fix to reports/catalogue_out.pl. Fixed in Koha 22.11.38, 24.11.16, 25.05.11, 25.11.05, 26.05.01, and 26.11.00 by replacing the raw concatenation with a parameterised placeholder.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.6)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:N/A:P

cvss3

Base Score: 7.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:L/A:L

cvss4

Base Score: 5.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:H/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:Y/R:X/V:C/RE:X/U:Amber

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-5513

SUMMARY

The Online Scheduling and Appointment Booking System – Bookly plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the 'bookly-customer-full-name' cookie in versions up to, and including, 27.2 due to insufficient input sanitization and output escaping. This makes it possible for unauthenticated attackers to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page. Exploitation requires 'Remember personal information in cookies' setting to be enabled (disabled by default).

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.2)

cvss3

Base Score: 7.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:L/I:L/A:N

Impact Score

2.7

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…